Author: Jimmy He PharmD, DSc

Challenging Cases in Antiretroviral Therapy and Panel Discussion

Challenging Cases in Antiretroviral Therapy and Panel Discussion Presenter: Michael S. Saag, MD On-Demand Webcast
DETAIL

Key Updates from CROI 2024

Key Updates from CROI 2024 Presenter: Paul E. Sax, MD On-Demand Webcast
DETAIL

Managing Substance Use Disorders: Opioids, Stimulants, and Alcohol

Managing Substance Use Disorders: Opioids, Stimulants, and Alcohol Presenter: Sandra A. Springer, MD On-Demand Webcast
DETAIL

From Data to Options: Advances in Sexually Transmitted Infection Prevention

From Data to Options: Advances in Sexually Transmitted Infection Prevention Presenter: Hyman Scott, MD, MPH On-Demand Webcast
DETAIL

(Article PDF) CROI 2018: Epidemic Trends and Advances in HIV Prevention

At the 2018 Conference on Retroviruses and Opportunistic Infections, trends in and risk factors for in HIV infection were highlighted. In the United States, new HIV diagnoses are highest in the South and among African Americans and are increasing in rural areas. Youth remain highly vulnerable to HIV infection globally. The epidemiology of HIV infections among people who inject drugs is changing, with overdose deaths, a major public health concern. Phylogenetics are being used to identify HIV transmission clusters and hotspots, which can inform prevention efforts. Vaginal microbial dysbiosis and proteomic alterations are associated with increased risk of HIV acquisition, as are the pregnancy and postpartum periods. HIV testing is a central first step for the HIV care and treatment continua, and several innovative strategies to expand HIV testing coverage and frequency show promise. Preexposure prophylaxis (PrEP) uptake is rapidly increasing in some cities, with reductions of new infections at the population level, but use is lower among African Americans and Latinos, youth, cis- and transgender women, and people who inject drugs. PrEP continuation remains a challenge. Two open-label extension studies of the dapivirine vaginal ring demonstrated high uptake, adherence, and reduced HIV infections. Several novel systemic and topical prevention agents show promise in non-human primates.

DETAIL
Jul
02

In Memoriam: Latesha Elopre, MD, MSPH

The IAS–USA is deeply saddened by the sudden and unexpected passing of Latesha Elopre, MD, a dedicated young physician and promising member of our Core Faculty. Her contributions to the study of infectious diseases and HIV prevention among vulnerable populations leave a lasting impact. Dr Elopre will be deeply missed and remembered for her dedication […]

DETAIL

Updated Recommendations From the 2024 International Antiviral Society-USA Panel

Following the US Food and Drug Administration approval of lenacapavir for HIV preexposure prophylaxis (PrEP) on June 18, 2025, and the release of new data on the use of tenofovir alafenamide/emtricitabine among cisgender women, the International Antiviral Society-USA (IAS-USA) panel submitted brief update of its 2024 special recommendations for HIV prevention to the Journal of [...]
DETAIL

Episode 50 – How Vaccines Get Approved in the US: The RSV Story and the Role of the ACIP – Dr Yvonne Maldonado

Episode 21 – New HIV Prevention: “What I’m Excited About” with Dr Raphael Landovitz

DETAIL

HIV 101 Webinar Rescheduled for September 25, 2025

We apologize for the oversight in the date for the IAS-USA webinar, HIV 101: Foundations of Management of People Who Are Newly Diagnosed With HIV, which was originally scheduled on the first day of Rosh Hashanah. We have rescheduled this webinar, and it will now be presented on Thursday, September 25, 2025, 12:00 PM - 1:30 PM PT. Those [...]
DETAIL

Closing Remarks

Michael S. Saag, MD, and Rajesh T. Gandhi, MD

DETAIL